Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome.

Brasa, Sarah; Mueller, Arne; Jacquemont, Sébastien; Hahne, Florian; Rozenberg, Izabela; Peters, Thomas; He, Yunsheng; McCormack, Christine; Gasparini, Fabrizio; Chibout, Salah-Dine; Grenet, Olivier; Moggs, Jonathan; Gomez-Mancilla, Baltazar; Terranova, Rémi

Brasa, Sarah; Mueller, Arne; Jacquemont, Sébastien; Hahne, Florian; Rozenberg, Izabela; Peters, Thomas; He, Yunsheng; McCormack, Christine; Gasparini, Fabrizio; Chibout, Salah-Dine; Grenet, Olivier; Moggs, Jonathan; Gomez-Mancilla, Baltazar; Terranova, Rémi.

Afiliação

Brasa S; Preclinical Safety, Translational Medicine, Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4057 Basel, Switzerland.
Mueller A; Preclinical Safety, Translational Medicine, Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4057 Basel, Switzerland.
Jacquemont S; Service de Génétique Médicale, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland.
Hahne F; Preclinical Safety, Translational Medicine, Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4057 Basel, Switzerland.
Rozenberg I; Neuroscience Translational Medicine, Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland.
Peters T; BioMarker Development, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Cambridge, MA USA.
He Y; BioMarker Development, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Cambridge, MA USA.
McCormack C; Clinical Diagnostics, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Cambridge, MA USA.
Gasparini F; Neuroscience, Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4057 Basel, Switzerland.
Chibout SD; Preclinical Safety, Translational Medicine, Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4057 Basel, Switzerland.
Grenet O; Preclinical Safety, Translational Medicine, Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4057 Basel, Switzerland.
Moggs J; Preclinical Safety, Translational Medicine, Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4057 Basel, Switzerland.
Gomez-Mancilla B; Neuroscience Translational Medicine, Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland.
Terranova R; Preclinical Safety, Translational Medicine, Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4057 Basel, Switzerland.

Clin Epigenetics ; 8: 15, 2016.

Article em En | MEDLINE | ID: mdl-26855684

Assuntos

Metilação de DNA; Epigênese Genética; Proteína do X Frágil da Deficiência Intelectual/genética; Síndrome do Cromossomo X Frágil/genética; Inativação Gênica; Adolescente; Adulto; Criança; Imunoprecipitação da Cromatina; Epigênese Genética/genética; Epigenômica; Proteína do X Frágil da Deficiência Intelectual/fisiologia; Marcadores Genéticos; Humanos; Masculino; Pessoa de Meia-Idade; Interferência de RNA; Adulto Jovem

Palavras-chave

5-hydroxymethylation (5hmC); Chromatin profiling; Clinical biomarker; Epigenetic silencing, FMR1; Fragile X syndrome (FXS)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Metilação de DNA / Inativação Gênica / Epigênese Genética / Proteína do X Frágil da Deficiência Intelectual / Síndrome do Cromossomo X Frágil Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Child / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google